Viromed Co., Ltd.

Helixmith Co., Ltd

Jin-A Chae

Seung Shin Yu

Kevin Friedman

Richard Morgan

Jae-Gyun Jeong

Chang-Wan Joo

Yeon Suk Cha

Dae Young Kim

Yu Jung Kim

The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.

Anti-Sialyl Tn chimeric antigen receptors

The invention relates to a cell line in which an expression construct is introduced into genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus El coding gene sequence of SEQ ID NO: 32 operatively linked to the promoter. The cell line of the invention is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the invention shows superior adenovirus producing ability, as compared with an HEK 293 cell which is one of conventional adenovirus producing cell lines.

Adenovirus producing novel cell line and the use thereof

Growing community of inventors

Seoul, South Korea

Jin-A Chae